What are your takeaways from the GPRC5D-Targeted CAR-T trial (Mailankody et al. NEJM Sept 2022) and any key differences compared to the BCMA directed products?  

I think it is hard to draw too many conclusions given that this is a first in human phase I study with only a small number of patients. What is promising here is that GPRC5D seems to be a good target for myeloma, even among patients with prior exposure to BCMA-targeted therapy. The population in thi...